Blood Cancer News and Research

RSS

Six-gene score could improve survival predictions for acute myeloid leukemia

The activity of six different genes can help determine patient survival of acute myeloid leukemia (AML), according to a study published today in Science Advances.

23 Oct 2026

New gene-editing platform gives doctors control over cell therapies

An Australian clinician-led research team has developed a gene-editing platform that could give doctors more control over cell therapies, making them more practical for patients with complex immune conditions.

20 Oct 2026

Blood Cancer United awards grant to diversify clinical trial access

Blood Cancer United, formerly The Leukemia & Lymphoma Society, has awarded $2.5 million to a research team led by Melissa Beauchemin, Ph.D., Assistant Professor at Columbia University School of Nursing, through its Equity in Access Research Program.

15 Oct 2026

Enhanced CAR T-cell therapy may improve treatment options for patients with B-cell blood cancers

Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers.

13 Oct 2026

Amphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

Amphista Therapeutics Limited ('Amphista'), a leader in the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced dosing of the first patient in a Phase 1 trial for its lead candidate, AMX-883. Initiated following authorization from the U.S. Food and Drug Administration in June 2026, the BRAMLIE trial will investigate the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk MDS.

From Amphista Therapeutics 12 Oct 2026

Dana-Farber research reveals possible new target for treatment of sickle cell and beta thalassemia

That pathway involves BACH2 and NRF2 and was discovered using a large genome-wide association study that enabled an analysis of genes related to fetal hemoglobin from a wide range of ancestries, including European, African, and Asian ancestries.

5 Oct 2026

Insurance hurdles and costs hinder access to blood cancer drugs

Patients with blood cancers often face major insurance hurdles and significant out-of-pocket costs when trying to access specialty oral anticancer medications, according to a new nationwide study led by researchers at the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2026

Scientists discover molecular pathway that controls cellular waste recycling

For years, TFEB has been regarded as one of the most promising therapeutic targets for restoring the cell's ability to clear and recycle waste.

30 Sep 2026

Pneumococcal disease may signal undiagnosed blood cancer

Severe pneumococcal disease requiring hospitalization, most commonly pneumonia, can be a sign of previously undiagnosed blood cancer and immunodeficiency in adult patients, according to a study from the University of Gothenburg.

30 Sep 2026

Multi-million dollar grants aim to advance hairy cell leukemia research

The Hairy Cell Leukemia Foundation and Blood Cancer United®, formerly The Leukemia & Lymphoma Society, today announced six new research grants as part of their ongoing strategic partnership to better understand what drives hairy cell leukemia and find better therapies on the road to cures for this rare form of blood cancer.

24 Sep 2026

NCI awards $3.46 million grant to study resistance to acute myeloid leukemia treatment

A five-year, $3.46 million grant from the National Cancer Institute recently was awarded to The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the University of California San Francisco (UCSF).

23 Sep 2026

EVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disorders

Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off.

21 Sep 2026

Daily vitamin C may benefit pre-cancerous blood disorder patients

Vitamin C is an essential nutrient that supports immune function, promotes wound healing and protects cells from molecular damage.

21 Sep 2026

CRISPR activation library uncovers gene driving lymphoma growth and resistance

Researchers have uncovered a previously unknown gene causing resistance to a leading blood cancer drug and several genes that accelerate lymphoma growth by using a powerful new CRISPR activation library.

18 Sep 2026

$15 million trial aims to improve treatment decisions for older AML patients

A newly funded national clinical trial initiative will gather critical evidence to determine the best treatment strategies for older adults with acute myeloid leukemia (AML), an aggressive, fast-moving blood cancer that leaves a substantial proportion of older patients facing uncertainty about whether to proceed to stem cell transplantation or continue non-transplant therapy.

27 Aug 2026

Younger mismatched donors offer new hope for blood cancer patients

Blood cancer patients who cannot find a closely matched stem cell donor may have more transplant options than previously thought.

21 Aug 2026

New study uncovers metabolic vulnerability in high-risk myelodysplastic syndromes

Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in the stem cells that drive high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer.

10 Aug 2026

QUANTUM trial tests immune-targeting approach for primary plasma cell leukemia

The Alliance for Clinical Trials in Oncology today announced the activation of The QUANTUM Trial (Alliance A062401), a clinical study designed to test a novel, immune-targeting approach for patients newly diagnosed with primary plasma cell leukemia (PCL).

30 Jul 2026

Medical breakthrough allows kidney transplant for patient with zero options

An international research team led by the Medical University of Vienna reports on a new treatment strategy that has made a kidney transplant possible for a patient with no realistic chance of receiving a suitable donor organ.

30 Jul 2026